Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Keefe

Showing results (131-140 of 255) with videos related to

Pageof 26
Sort By:
Schizophrenia Research|August 30, 2011
Substance use and schizophrenia: adverse correlates in the CATIE study sampleKarin E Kerfoot, Robert A Rosenheck, Ismene L Petrakis, et al.
Journal of Visualized Experiments : Jove|May 7, 2014
Development of a virtual reality assessment of everyday living skillsStacy A Ruse, Vicki G Davis, Alexandra S Atkins, et al.
Cognitive Neuropsychiatry|November 14, 2012
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRSBreno Fiúza Cruz, Camilo Brandão de Resende, Mery Natali Abreu, et al.
Psychiatry Research|November 20, 2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosisMariapaola Barbato, Mark A Colijn, Richard S E Keefe, et al.
The American Journal of Psychiatry|September 14, 2013
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal studyMadeline H Meier, Avshalom Caspi, Abraham Reichenberg, et al.
The Journal of Prevention of Alzheimer'S Disease|December 1, 2015
Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)A S Atkins, I Stroescu, N B Spagnola, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 27, 2020
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disordersElan A Cohen, Howard H Hassman, Larry Ereshefsky, et al.
Innovations in Clinical Neuroscience|March 18, 2024
Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways ForwardWilliam P Horan, Gary Sachs, Dawn I Velligan, et al.
Schizophrenia Bulletin|August 12, 2003
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationaleRichard S E Keefe, Richard C Mohs, Robert M Bilder, et al.
Schizophrenia Research. Cognition|July 26, 2017
Disrupted latent inhibition in individuals at ultra high-risk for developing psychosisMichael Kraus, Attilio Rapisarda, Max Lam, et al.
Pageof 26

Showing results (131-140 of 255) with videos related to

Sort By:
Pageof 26
Schizophrenia Research|August 30, 2011
Substance use and schizophrenia: adverse correlates in the CATIE study sampleKarin E Kerfoot, Robert A Rosenheck, Ismene L Petrakis, et al.
Journal of Visualized Experiments : Jove|May 7, 2014
Development of a virtual reality assessment of everyday living skillsStacy A Ruse, Vicki G Davis, Alexandra S Atkins, et al.
Cognitive Neuropsychiatry|November 14, 2012
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRSBreno Fiúza Cruz, Camilo Brandão de Resende, Mery Natali Abreu, et al.
Psychiatry Research|November 20, 2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosisMariapaola Barbato, Mark A Colijn, Richard S E Keefe, et al.
The American Journal of Psychiatry|September 14, 2013
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal studyMadeline H Meier, Avshalom Caspi, Abraham Reichenberg, et al.
The Journal of Prevention of Alzheimer'S Disease|December 1, 2015
Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)A S Atkins, I Stroescu, N B Spagnola, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 27, 2020
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disordersElan A Cohen, Howard H Hassman, Larry Ereshefsky, et al.
Innovations in Clinical Neuroscience|March 18, 2024
Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways ForwardWilliam P Horan, Gary Sachs, Dawn I Velligan, et al.
Schizophrenia Bulletin|August 12, 2003
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationaleRichard S E Keefe, Richard C Mohs, Robert M Bilder, et al.
Schizophrenia Research. Cognition|July 26, 2017
Disrupted latent inhibition in individuals at ultra high-risk for developing psychosisMichael Kraus, Attilio Rapisarda, Max Lam, et al.
Pageof 26